Impax Laboratories, Inc. (NASDAQ: IPXL) today confirmed that the U.S. Food and Drug Administration (FDA) has granted tentative approval of the Company's Abbreviated New Drug Application (ANDA) for generic version of Opana® ER (oxymorphone hydrochloride) 5, 7.5, 10, 15, 20, 30 and 40 mg tablets. Endo Pharmaceuticals Inc. markets Opana® ER for the treatment of moderate to severe pain. According to Wolters Kluwer Health, U.S. sales of Opana® ER tablets were approximately $241 million for the 12 months ended March 31, 2010. Source Impax Laboratories, Inc...
More...
More...